Leerink Partners raised its price target on Mirati Therapeutics (NASDAQ: MRTX) to $9.00 (from $7.00) while maintaining a Market ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Mirati Therapeutics (MRTX) Trades at High, Up 150%September 15, 2017 10:54 AM After-Hours Stock Movers 09/14: (MRTX) (LPTH) (GNW) Higher; (TTOO) (ORCL) (MRNS) Lower (more...)September 14, 2017 6:20 PM Mirati Therapeutics (MRTX) Reports Positive Preliminary Data From On-Going Clinical Trials of Sitravatinib in Non-Small Cell Lung CancerSeptember 14, 2017 4:34 PM Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung CancerSeptember 14, 2017 4:33 PM Mirati Therapeutics (MRTX) Halted, News PendingSeptember 14, 2017 4:27 PM